AL137 lead anti-Aβ antibody enters Phase I trials
Neurodegeneration-focused company ALEC is advancing its blood-brain barrier platform. Its lead anti-Aβ antibody AL137 has entered Phase I trials, while additional siRNA and enzyme therapies are progressing toward the clinic.